Lipocine's lpcn 1144 met non-alcoholic steatohepatitis ("nash") resolution regulatory endpoint in phase 2 lift study

Salt lake city, aug. 25, 2021 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline 36-week results from its phase 2 proof of concept lift (" liver  f at intervention with oral  t estosterone") clinical study, nct04134091, investigating lpcn 1144 in men with biopsy-confirmed nash. currently, there are no approved treatments for nash, a leading cause of liver failure and liver transplantation globally.
LPCN Ratings Summary
LPCN Quant Ranking